Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical K101 for distal subungual onychomycosis
2009-013261-26Phase 3Terminated
- Sponsor
- Moberg Pharma AB
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in onychomycosis comparing K101 with Placebo (2 arms). Primary endpoint: Mycological cure of target nail at 12 months + 2 weeks washout. Started Jul 2009; status: terminated.
02
Drugs
chlorfenson
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2009-013261-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013261-26.